Ready-made antibodies circulating for months, waiting to neutralize
As Europe's vaccination momentum slows and infection rates climb once more, the continent's medicines regulator has approved a new tool in the long effort to protect those most vulnerable to COVID-19. AstraZeneca's Evusheld — an antibody therapy rather than a vaccine — received clearance from the European Medicines Agency for use in immunocompromised individuals aged 12 and older who cannot rely on their own immune systems to respond to traditional inoculation. The approval reflects a quiet but significant evolution in pandemic strategy: when the body cannot be trained to defend itself, science can deliver the defenses directly.
- Europe faces a troubling paradox — adult vaccination rates have plateaued above 83%, yet new COVID-19 cases are rising again, leaving millions of immunocompromised people dangerously exposed.
- Evusheld works not by teaching the immune system but by bypassing it entirely, flooding the bloodstream with ready-made antibodies that can neutralize the virus for at least six months.
- Clinical trials showed a 77% reduction in symptomatic COVID-19 risk, and laboratory studies confirmed the drug retains effectiveness against Omicron variants, including the fast-spreading BA.2 sub-variant.
- AstraZeneca joins Regeneron and the Eli Lilly–GSK–Vir partnership in a growing field of antibody-based options, signaling that Europe's pandemic response is diversifying beyond the vaccine-only approach.
- Formal confirmation from the European Commission is expected within days, marking a procedural finish line that typically follows the EMA's recommendation without delay.
Europe's medicines regulator approved AstraZeneca's Evusheld on Thursday — an antibody drug designed to prevent COVID-19 — at a moment when the continent is caught between stalling vaccination campaigns and rising case counts. The European Medicines Agency's decision arrives as health systems search for new ways to protect those the vaccines cannot adequately reach.
Unlike vaccines, Evusheld does not ask the immune system to learn. It delivers laboratory-engineered antibodies directly into the bloodstream, where they remain active for months, ready to neutralize the virus on contact. The drug is cleared for adults and adolescents aged 12 and older who have not yet been infected — and is especially valuable for people whose compromised immune systems make traditional vaccines largely ineffective.
The clinical evidence is encouraging: Evusheld reduced symptomatic COVID-19 risk by 77%, with protection holding for at least six months. AstraZeneca also reported that the therapy neutralizes Omicron variants in laboratory conditions, including the BA.2 sub-variant, and may slow disease progression when given shortly after infection.
AstraZeneca enters a field already occupied by Regeneron and the Eli Lilly–GlaxoSmithKline–Vir Biotechnology alliance, whose antibody treatments are already in use across Europe. Together, these approvals reflect a broader strategic turn: as vaccination rates plateau just above 83% and new variants continue to emerge, regulators are building a more layered defense — one that can reach the patients traditional tools have left behind. The European Commission is expected to formally confirm the EMA's recommendation within days.
Europe's medicines regulator gave the green light on Thursday to AstraZeneca's Evusheld, an antibody drug designed to prevent COVID-19 infections. The timing matters: across the continent, new cases are climbing again, and the push to vaccinate adults has stalled. The European Medicines Agency's recommendation arrives as the region searches for new tools to manage a virus that refuses to disappear.
Evusheld is not a vaccine. It works differently. While vaccines train the immune system to recognize and fight the virus on its own, Evusheld delivers ready-made antibodies—laboratory-engineered proteins that circulate in the bloodstream for months, ready to neutralize the virus if exposure occurs. The EMA cleared it for use in adults and adolescents aged 12 and older who have not yet been infected with COVID-19. The drug is particularly valuable for people whose immune systems are too compromised to mount an effective response to vaccination, a population for whom traditional vaccines offer little protection.
Other companies have already staked claims in this space. Regeneron Pharmaceuticals developed an antibody drug approved in Europe for both treating and preventing COVID-19. Eli Lilly and Co, working with partners GlaxoSmithKline and Vir Biotechnology, have antibody treatments on the market for patients already sick with the virus. AstraZeneca's entry into prevention represents a widening arsenal of options as Europe confronts a stalled vaccination campaign. Adult inoculation rates have plateaued just above 83 percent—high by global standards, but not high enough to prevent the wave of infections now sweeping across the region.
In clinical trials, Evusheld reduced the risk of developing symptomatic COVID-19 by 77 percent, with protection lasting at least six months. AstraZeneca reported separately that the drug retained its ability to neutralize Omicron variants in laboratory studies, including the highly transmissible BA.2 sub-variant. The company also noted that the therapy can prevent disease progression when administered soon after infection, suggesting utility beyond pure prevention.
The EMA's decision on Thursday is expected to be formally confirmed by the European Commission in the coming days, a procedural step that typically moves quickly once the medicines agency has weighed in. The approval reflects a broader shift in pandemic strategy: as vaccination campaigns lose momentum and new variants continue to emerge, regulators and health systems are turning to complementary approaches. For immunocompromised patients—those with weakened immune systems from disease, age, or medical treatment—Evusheld offers something vaccines cannot: passive immunity delivered directly, without requiring the body's own defenses to do the work.
Citas Notables
AstraZeneca said the drug retained neutralising activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study— AstraZeneca
La Conversación del Hearth Otra perspectiva de la historia
Why does this drug matter now, specifically? Europe has vaccines.
Vaccines work brilliantly if your immune system can respond to them. But some people can't—their bodies are too weak to build antibodies from a shot. For them, Evusheld is the first real option.
So it's not replacing vaccines.
No. It's filling a gap vaccines can't reach. And it comes at a moment when Europe's vaccination rate has basically stopped climbing.
The 77 percent efficacy—how does that compare to what we expect?
It's solid. Not perfect, but it lasts six months, and it works against the variants circulating now. For people who can't use vaccines, that's transformative.
Who decides if someone gets it? Is it automatic for immunocompromised people?
That's the question regulators and doctors will have to answer. The approval is there. Implementation—who qualifies, how it's distributed—that's still being worked out.
And if this works, what comes next?
More of these antibody drugs, probably. We're moving toward a world where prevention isn't just vaccination. It's layered.